Assets
| Type | Time | Amount | Unit |
|---|---|---|---|
| ifrs-full:Assets | 2025-12-31 | 1375553000 | vEUR |
| ifrs-full:Assets | 2024-12-31 | 1056004000 | vEUR |
| ifrs-full:Assets | 2023-12-31 | 1184005000 | vEUR |
| ifrs-full:Assets | 2022-12-31 | 446734000 | vEUR |
| ifrs-full:Assets | 2021-12-31 | 283420000 | vEUR |
Revenue
| Type | Start date | End date | Amount | Unit |
|---|---|---|---|---|
| ifrs-full:Revenue | 2025-01-01 | 2025-12-31 | 2504841000 | vEUR |
| ifrs-full:Revenue | 2024-01-01 | 2024-12-31 | 2367751000 | vEUR |
| ifrs-full:Revenue | 2023-01-01 | 2023-12-31 | 2017348000 | vEUR |
| ifrs-full:Revenue | 2022-01-01 | 2022-12-31 | 509920000 | vEUR |
| ifrs-full:Revenue | 2021-01-01 | 2021-12-31 | 373940000 | vEUR |
XML
See the xml submitted here:
XML: http://regnskaber.virk.dk/54008183/amNsb3VkczovLzAzLzhlL2Q4L2RjLzViL2Y4NGUtNDczYS04YjhjLWM3YzQxMTZjYTE5MA.xml
Separator
The full data:
<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance"
xmlns="http://www.w3.org/1999/xhtml"
xmlns:arr="http://xbrl.dcca.dk/arr"
xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16"
xmlns:cmn="http://xbrl.dcca.dk/cmn"
xmlns:sob="http://xbrl.dcca.dk/sob"
xmlns:link="http://www.xbrl.org/2003/linkbase"
xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2019-03-27/ifrs-full"
xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
xmlns:ix="http://www.xbrl.org/2013/inlineXBRL"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xmlns:mrv="http://xbrl.dcca.dk/mrv"
xmlns:fsa="http://xbrl.dcca.dk/fsa"
xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
xmlns:ifrs-ext="http://archprod.service.eogs.dk/taxonomy/20241001"
xmlns:gsd="http://xbrl.dcca.dk/gsd"
xmlns:xlink="http://www.w3.org/1999/xlink"
xml:lang="en">
<link:schemaRef xlink:href="http://archprod.service.eogs.dk/taxonomy/20241001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20241001.xsd"
xlink:type="simple"
xml:lang="en"/>
<xbrli:context id="ctx1">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx2">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
<cmn:memberOfBoardIdentifier>0</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx3">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>0</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx4">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx5">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx36">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
<cmn:auditorIdentifier>1</cmn:auditorIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx35">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
<cmn:auditorIdentifier>0</cmn:auditorIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx6">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-01-01</xbrli:startDate>
<xbrli:endDate>2024-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx9">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx10">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-01-01</xbrli:startDate>
<xbrli:endDate>2022-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx11">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx7">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2025-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx15">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>0</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx8">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2024-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx16">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-01-01</xbrli:startDate>
<xbrli:endDate>2024-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>1</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx12">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2023-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx17">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>2</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx13">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2022-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx18">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-01-01</xbrli:startDate>
<xbrli:endDate>2022-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>3</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx14">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx19">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>4</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx20">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>5</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx21">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-01-01</xbrli:startDate>
<xbrli:endDate>2024-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>6</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx22">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>7</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx23">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-01-01</xbrli:startDate>
<xbrli:endDate>2022-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>8</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx28">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-01-01</xbrli:startDate>
<xbrli:endDate>2022-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>13</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx33">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-01-01</xbrli:startDate>
<xbrli:endDate>2022-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>18</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx24">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>9</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx29">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>14</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx27">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>12</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx26">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-01-01</xbrli:startDate>
<xbrli:endDate>2024-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>11</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx25">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>10</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx34">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>19</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx32">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>17</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-01-01</xbrli:startDate>
<xbrli:endDate>2024-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>16</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx30">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>15</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:unit id="vEUR">
<xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<gsd:ReportingPeriodStartDate contextRef="ctx1" id="fact1000">2025-01-01</gsd:ReportingPeriodStartDate>
<fsa:ClassOfReportingEntity contextRef="ctx1" id="fact1135" xml:lang="en">Regnskabsklasse C, stor virksomhed</fsa:ClassOfReportingEntity>
<gsd:InformationOnTypeOfSubmittedReport contextRef="ctx1" id="fact1641" xml:lang="en">Annual report</gsd:InformationOnTypeOfSubmittedReport>
<gsd:IdentificationNumberCvrOfSubmittingEnterprise contextRef="ctx1" id="fact1642" xml:lang="en">34209936</gsd:IdentificationNumberCvrOfSubmittingEnterprise>
<gsd:NameOfSubmittingEnterprise contextRef="ctx1" id="fact1643" xml:lang="en">Grant Thornton, Statsautoriseret Revisionspartnerselskab</gsd:NameOfSubmittingEnterprise>
<gsd:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="ctx1" id="fact1644" xml:lang="en">Lautrupsgade 11</gsd:AddressOfSubmittingEnterpriseStreetAndNumber>
<gsd:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="ctx1" id="fact1645" xml:lang="en">2100 København Ã</gsd:AddressOfSubmittingEnterprisePostcodeAndTown>
<gsd:ToolForPreparingTheXBRLInstanceDocument contextRef="ctx1" id="fact1646" xml:lang="en">xWizard version 1.1.1540.0, by EasyX Aps. www.easyx.eu</gsd:ToolForPreparingTheXBRLInstanceDocument>
<gsd:PrecedingReportingPeriodStartDate contextRef="ctx1" id="fact1647" xml:lang="en">2024-01-01</gsd:PrecedingReportingPeriodStartDate>
<gsd:PredingReportingPeriodEndDate contextRef="ctx1" id="fact1648" xml:lang="en">2024-12-31</gsd:PredingReportingPeriodEndDate>
<cmn:TypeOfAuditorAssistance contextRef="ctx1" id="fact1649" xml:lang="en">Auditor's report on audited financial statements</cmn:TypeOfAuditorAssistance>
<arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements contextRef="ctx1" id="fact1650" xml:lang="en">Basis for Opinion</arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements>
<arr:TypeOfModifiedOpinionOnAuditedFinancialStatements contextRef="ctx1" id="fact1651" xml:lang="en">Opinion</arr:TypeOfModifiedOpinionOnAuditedFinancialStatements>
<gsd:ReportingPeriodEndDate contextRef="ctx1" id="fact1001">2025-12-31</gsd:ReportingPeriodEndDate>
<gsd:DateOfGeneralMeeting contextRef="ctx1" id="fact1002">2026-06-18</gsd:DateOfGeneralMeeting>
<gsd:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="ctx1" id="fact1003" xml:lang="en">Mads Wilhelm Ãckenholt Larsen</gsd:NameAndSurnameOfChairmanOfGeneralMeeting>
<sob:StatementByExecutiveAndSupervisoryBoards contextRef="ctx1" id="fact1004" xml:lang="en">Management's statement  Today, the Board of Directors and the Managing Director have approved the annual report of Novo Nordisk  Denmark A/S for the financial year 1 January - 31 December 2025.  The annual report has been prepared in accordance with the Danish Financial Statements Act.  We consider the chosen accounting policy to be appropriate, and in our opinion, the financial statements give a true  and fair view of the financial position of the Company at 31 December 2025 and of the results of the Company's  operations for the financial year 1 January â 31 December 2025.  Further, in our opinion, the Management's review is prepared in accordance with relevant laws and regulations and  contains a fair review of the development of the business and financial matters, the results for the year and the  financial position, together with a description of the risks and uncertainties if any.  </sob:StatementByExecutiveAndSupervisoryBoards>
<sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="ctx1" id="fact1014" xml:lang="en">We recommend that the annual report be approved at the Annual General Meeting.</sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting>
<sob:PlaceOfSignatureOfStatement contextRef="ctx1" id="fact1015" xml:lang="en">Copenhagen</sob:PlaceOfSignatureOfStatement>
<sob:DateOfApprovalOfAnnualReport contextRef="ctx1" id="fact1016">2026-06-18</sob:DateOfApprovalOfAnnualReport>
<cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx2" id="fact1652" xml:lang="en">Mads Wilhelm Ãckenholt Larsen</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx3" id="fact1654" xml:lang="en">Jonas Emil Kongshøj Larsen</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx4" id="fact1658" xml:lang="en">Jeppe Theisen</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx5" id="fact1660" xml:lang="en">David Marcus Svensson</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx3" id="fact1656" xml:lang="en">Chairman</cmn:TitleOfMemberOfSupervisoryBoard>
<arr:IndependentAuditorsReportsAudit contextRef="ctx1" id="fact1017" xml:lang="en">Independent auditor's report</arr:IndependentAuditorsReportsAudit>
<arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements contextRef="ctx1" id="fact1018" xml:lang="en">To the Shareholder of Novo Nordisk Denmark A/S</arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements>
<arr:OpinionOnAuditedFinancialStatements contextRef="ctx1" id="fact1019" xml:lang="en">Opinion  We have audited the financial statements of Novo Nordisk Denmark A/S for the financial year 01.01.2025 -  31.12.2025, which comprise the income statement, balance sheet, statement of changes in equity, and notes,  including a summary of significant accounting policies. The financial statements are prepared in accordance with the  Danish Financial Statements Act.  In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2025 and  of the results of its operations for the financial year 01.01.2025 - 31.12.2025 in accordance with the Danish Financial  Statements Act.  </arr:OpinionOnAuditedFinancialStatements>
<arr:DescriptionOfQualificationsOfAuditedFinancialStatements contextRef="ctx1" id="fact1027" xml:lang="en">Basis for Opinion  We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements  applicable in Denmark. Our responsibilities under those standards and requirements are further described in the  "Auditorâs responsibilities for the audit of the financial statements" section of this auditorâs report. We are  independent of the Entity in accordance with the International Ethics Standards Board for Accountantsâ International  Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in  Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the  IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis  for our opinion.  </arr:DescriptionOfQualificationsOfAuditedFinancialStatements>
<arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="ctx1" id="fact1036" xml:lang="en">Managementâs Responsibilities for the Financial Statements  Management is responsible for the preparation of financial statements that give a true and fair view in accordance  with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to  enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.  In preparing the financial statements, Management is responsible for assessing the Entityâs ability to continue as a  going concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis  of accounting in preparing the financial statements unless Management either intends to liquidate the Entity or to  cease operations, or has no realistic alternative but to do so.  </arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements>
<arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="ctx1" id="fact1044" xml:lang="en">Auditorâs Responsibilities for the Audit of the Financial Statements  Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from  material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion.  Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with  ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it  exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate,  they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial  statements.  As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we  exercise professional judgement and maintain professional scepticism throughout the audit. We also: Â ï· Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or  error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is  sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material  misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion,  forgery, intentional omissions, misrepresentations, or the override of internal control. Â ï· Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are  appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the  Entityâs internal control. Â ï· Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and  related disclosures made by Management. Â ï· Conclude on the appropriateness of Managementâs use of the going concern basis of accounting in preparing  the financial statements, and, based on the audit evidence obtained, whether a material uncertainty exists  related to events or conditions that may cast significant doubt on the Entityâs ability to continue as a going  concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditorâs  report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify  our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditorâs report.  However, future events or conditions may cause the Entity to cease to continue as a going concern. Â ï· Evaluate the overall presentation, structure and content of the financial statements, including the disclosures  in the notes, and whether the financial statements represent the underlying transactions andevents in a  manner that gives a true and fair view.  We communicate with those charged with governance regarding, among other matters, the planned scope and timing  of the audit and significant audit findings, including any significant deficiencies in internal control that we identify  during our audit.  </arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed>
<arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="ctx1" id="fact1082" xml:lang="en">Statement on Managementâs Review  Management is responsible for Managementâs Review.  Our opinion on the financial statements does not cover Managementâs Review, and we do not express any form of  assurance conclusion thereon.  In connection with our audit of the financial statements, our responsibility is to read Managementâs Review and, in  doing so, consider whether Managementâs Review is materially inconsistent with the financial statements or our  knowledge obtained during the audit, or otherwise appears to be materially misstated.  Moreover, it is our responsibility to consider whether Managementâs Review provides the information required by  relevant law and regulations.  Based on the work we have performed, we conclude that the Managementâs Review is in accordance with the  financial statements and has been prepared in accordance with the requirements in the relevant law and regulations.  We did not identify any material misstatement of Managementâs Review.  </arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements>
<arr:SignatureOfAuditorsPlace contextRef="ctx1" id="fact1094" xml:lang="en">Copenhagen</arr:SignatureOfAuditorsPlace>
<arr:SignatureOfAuditorsDate contextRef="ctx1" id="fact1095">2026-06-18</arr:SignatureOfAuditorsDate>
<cmn:NameOfAuditFirm contextRef="ctx36" id="fact1698" xml:lang="en">Deloitte Statsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm>
<cmn:NameOfAuditFirm contextRef="ctx35" id="fact1682" xml:lang="en">Deloitte Statsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm>
<cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx36" id="fact1697">33963556</cmn:IdentificationNumberCvrOfAuditFirm>
<cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx35" id="fact1686">33963556</cmn:IdentificationNumberCvrOfAuditFirm>
<cmn:NameAndSurnameOfAuditor contextRef="ctx35" id="fact1687" xml:lang="en">Sumit Sudan</cmn:NameAndSurnameOfAuditor>
<cmn:NameAndSurnameOfAuditor contextRef="ctx36" id="fact1694" xml:lang="en">Ãzgün Acigora</cmn:NameAndSurnameOfAuditor>
<cmn:DescriptionOfAuditor contextRef="ctx35" id="fact1688" xml:lang="en">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
<cmn:IdentificationNumberOfAuditor contextRef="ctx35" id="fact1689" xml:lang="en">mne33716</cmn:IdentificationNumberOfAuditor>
<cmn:DescriptionOfAuditor contextRef="ctx36" id="fact1695" xml:lang="en">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
<cmn:IdentificationNumberOfAuditor contextRef="ctx36" id="fact1696" xml:lang="en">mne48478</cmn:IdentificationNumberOfAuditor>
<gsd:NameOfReportingEntity contextRef="ctx1" id="fact1096" xml:lang="en">Novo Nordisk Denmark A/S</gsd:NameOfReportingEntity>
<gsd:AddressOfReportingEntityStreetName contextRef="ctx1" id="fact1097" xml:lang="en">Kay Fiskers Plads</gsd:AddressOfReportingEntityStreetName>
<gsd:AddressOfReportingEntityStreetBuildingIdentifier contextRef="ctx1" id="fact1098" xml:lang="en">10, 7.</gsd:AddressOfReportingEntityStreetBuildingIdentifier>
<gsd:AddressOfReportingEntityPostCodeIdentifier contextRef="ctx1" id="fact1099" xml:lang="en">2300</gsd:AddressOfReportingEntityPostCodeIdentifier>
<gsd:AddressOfReportingEntityDistrictName contextRef="ctx1" id="fact1100" xml:lang="en">København S</gsd:AddressOfReportingEntityDistrictName>
<gsd:TelephoneNumberOfReportingEntity contextRef="ctx1" id="fact1101" xml:lang="en">+45 35 35 00 02</gsd:TelephoneNumberOfReportingEntity>
<gsd:IdentificationNumberCvrOfReportingEntity contextRef="ctx1" id="fact1102">38180045</gsd:IdentificationNumberCvrOfReportingEntity>
<gsd:DateOfFoundationOfReportingEntity contextRef="ctx1" id="fact1103">2016-11-14</gsd:DateOfFoundationOfReportingEntity>
<gsd:RegisteredOfficeOfReportingEntity contextRef="ctx1" id="fact1104" xml:lang="en">Copenhagen</gsd:RegisteredOfficeOfReportingEntity>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx3" id="fact1655" xml:lang="en">Jonas Emil Kongshøj Larsen</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx3" id="fact1657" xml:lang="en">Chairman</cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx4" id="fact1659" xml:lang="en">Jeppe Theisen</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx5" id="fact1661" xml:lang="en">David Marcus Svensson</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx2" id="fact1653" xml:lang="en">Mads Wilhelm Ãckenholt Larsen</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
<cmn:NameOfAuditFirm contextRef="ctx35" id="fact1684" xml:lang="en">Deloitte Statsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm>
<gsd:AddressOfAuditorStreetName contextRef="ctx35" id="fact1692" xml:lang="en">Weidekampsgade</gsd:AddressOfAuditorStreetName>
<gsd:AddressOfAuditorStreetBuildingIdentifier contextRef="ctx35" id="fact1693" xml:lang="en">6</gsd:AddressOfAuditorStreetBuildingIdentifier>
<gsd:AddressOfAuditorPostCodeIdentifier contextRef="ctx35" id="fact1690" xml:lang="en">2300</gsd:AddressOfAuditorPostCodeIdentifier>
<gsd:AddressOfAuditorDistrictName contextRef="ctx35" id="fact1691" xml:lang="en">København S</gsd:AddressOfAuditorDistrictName>
<mrv:DescriptionOfKeyFiguresAndFinancialRatios contextRef="ctx1" id="fact1565" xml:lang="en">Financial highlights</mrv:DescriptionOfKeyFiguresAndFinancialRatios>
<fsa:Revenue contextRef="ctx1" decimals="-3" id="fact1701" unitRef="vEUR">2504841000</fsa:Revenue>
<fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx1" decimals="-3" id="fact1709" unitRef="vEUR">145788000</fsa:ProfitLossFromOrdinaryOperatingActivities>
<fsa:ResultsFromNetFinancials contextRef="ctx1" decimals="-3" id="fact1720" unitRef="vEUR">10716000</fsa:ResultsFromNetFinancials>
<fsa:Revenue contextRef="ctx6" decimals="-3" id="fact1726" unitRef="vEUR">2367751000</fsa:Revenue>
<fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx6" decimals="-3" id="fact1734" unitRef="vEUR">101371000</fsa:ProfitLossFromOrdinaryOperatingActivities>
<fsa:ResultsFromNetFinancials contextRef="ctx6" decimals="-3" id="fact1745" unitRef="vEUR">14332000</fsa:ResultsFromNetFinancials>
<fsa:Revenue contextRef="ctx9" decimals="-3" id="fact1814" unitRef="vEUR">2017348000</fsa:Revenue>
<fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx9" decimals="-3" id="fact1815" unitRef="vEUR">101021000</fsa:ProfitLossFromOrdinaryOperatingActivities>
<fsa:ResultsFromNetFinancials contextRef="ctx9" decimals="-3" id="fact1816" unitRef="vEUR">6891000</fsa:ResultsFromNetFinancials>
<fsa:Revenue contextRef="ctx10" decimals="-3" id="fact1823" unitRef="vEUR">509920000</fsa:Revenue>
<fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx10" decimals="-3" id="fact1824" unitRef="vEUR">42630000</fsa:ProfitLossFromOrdinaryOperatingActivities>
<fsa:ResultsFromNetFinancials contextRef="ctx10" decimals="-3" id="fact1825" unitRef="vEUR">1404000</fsa:ResultsFromNetFinancials>
<fsa:Revenue contextRef="ctx11" decimals="-3" id="fact1832" unitRef="vEUR">373940000</fsa:Revenue>
<fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx11" decimals="-3" id="fact1833" unitRef="vEUR">30232000</fsa:ProfitLossFromOrdinaryOperatingActivities>
<fsa:ResultsFromNetFinancials contextRef="ctx11" decimals="-3" id="fact1834" unitRef="vEUR">-1586000</fsa:ResultsFromNetFinancials>
<fsa:ProfitLoss contextRef="ctx11" decimals="-3" id="fact1835" unitRef="vEUR">21405000</fsa:ProfitLoss>
<fsa:ProfitLoss contextRef="ctx1" decimals="-3" id="fact1716" unitRef="vEUR">118803000</fsa:ProfitLoss>
<fsa:ProfitLoss contextRef="ctx6" decimals="-3" id="fact1741" unitRef="vEUR">86129000</fsa:ProfitLoss>
<fsa:ProfitLoss contextRef="ctx9" decimals="-3" id="fact1817" unitRef="vEUR">81998000</fsa:ProfitLoss>
<fsa:ProfitLoss contextRef="ctx10" decimals="-3" id="fact1826" unitRef="vEUR">33548000</fsa:ProfitLoss>
<fsa:Assets contextRef="ctx7" decimals="-3" id="fact1763" unitRef="vEUR">1375553000</fsa:Assets>
<mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx15" decimals="-3" id="fact1847" unitRef="vEUR">5478000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
<fsa:Assets contextRef="ctx8" decimals="-3" id="fact1795" unitRef="vEUR">1056004000</fsa:Assets>
<mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx16" decimals="-3" id="fact1848" unitRef="vEUR">18571000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
<fsa:Assets contextRef="ctx12" decimals="-3" id="fact1841" unitRef="vEUR">1184005000</fsa:Assets>
<mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx17" decimals="-3" id="fact1849" unitRef="vEUR">19003000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
<fsa:Assets contextRef="ctx13" decimals="-3" id="fact1843" unitRef="vEUR">446734000</fsa:Assets>
<mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx18" decimals="-3" id="fact1850" unitRef="vEUR">23612000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
<fsa:Equity contextRef="ctx13" decimals="-3" id="fact1844" unitRef="vEUR">49140000</fsa:Equity>
<fsa:Assets contextRef="ctx14" decimals="-3" id="fact1845" unitRef="vEUR">283420000</fsa:Assets>
<mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx19" decimals="-3" id="fact1851" unitRef="vEUR">4375000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx19" id="fact1666" xml:lang="en">Investments in property, plant and equipment</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx18" id="fact1665" xml:lang="en">Investments in property, plant and equipment</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx17" id="fact1664" xml:lang="en">Investments in property, plant and equipment</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx16" id="fact1663" xml:lang="en">Investments in property, plant and equipment</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx15" id="fact1662" xml:lang="en">Investments in property, plant and equipment</mrv:NameOfKeyFigureOrFinancialRatio>
<fsa:Equity contextRef="ctx7" decimals="-3" id="fact1769" unitRef="vEUR">134570000</fsa:Equity>
<fsa:Equity contextRef="ctx8" decimals="-3" id="fact1801" unitRef="vEUR">101767000</fsa:Equity>
<fsa:Equity contextRef="ctx12" decimals="-3" id="fact1842" unitRef="vEUR">97638000</fsa:Equity>
<fsa:Equity contextRef="ctx14" decimals="-3" id="fact1846" unitRef="vEUR">36993000</fsa:Equity>
<fsa:AverageNumberOfEmployees contextRef="ctx1" decimals="0" id="fact1718" unitRef="pure">299</fsa:AverageNumberOfEmployees>
<fsa:AverageNumberOfEmployees contextRef="ctx6" decimals="0" id="fact1743" unitRef="pure">294</fsa:AverageNumberOfEmployees>
<fsa:AverageNumberOfEmployees contextRef="ctx9" decimals="0" id="fact1818" unitRef="pure">236</fsa:AverageNumberOfEmployees>
<fsa:AverageNumberOfEmployees contextRef="ctx10" decimals="0" id="fact1827" unitRef="pure">200</fsa:AverageNumberOfEmployees>
<fsa:AverageNumberOfEmployees contextRef="ctx11" decimals="0" id="fact1836" unitRef="pure">176</fsa:AverageNumberOfEmployees>
<mrv:OperatingMargin contextRef="ctx1" decimals="1" id="fact1721" unitRef="pure">5.8</mrv:OperatingMargin>
<mrv:GrossMargin contextRef="ctx1" decimals="1" id="fact1722" unitRef="pure">19.9</mrv:GrossMargin>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx20" decimals="1" id="fact1852" unitRef="pure">6.4</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:OperatingMargin contextRef="ctx6" decimals="1" id="fact1746" unitRef="pure">4.3</mrv:OperatingMargin>
<mrv:GrossMargin contextRef="ctx6" decimals="1" id="fact1747" unitRef="pure">23.8</mrv:GrossMargin>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx21" decimals="1" id="fact1853" unitRef="pure">4.8</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:OperatingMargin contextRef="ctx9" decimals="1" id="fact1819" unitRef="pure">5</mrv:OperatingMargin>
<mrv:GrossMargin contextRef="ctx9" decimals="1" id="fact1820" unitRef="pure">23.5</mrv:GrossMargin>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx22" decimals="1" id="fact1854" unitRef="pure">5.5</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:OperatingMargin contextRef="ctx10" decimals="1" id="fact1828" unitRef="pure">8.4</mrv:OperatingMargin>
<mrv:GrossMargin contextRef="ctx10" decimals="1" id="fact1829" unitRef="pure">65.3</mrv:GrossMargin>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx23" decimals="1" id="fact1855" unitRef="pure">10.3</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx28" decimals="1" id="fact1860" unitRef="pure">11.7</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx33" decimals="1" id="fact1865" unitRef="pure">123</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:ReturnOnEquity contextRef="ctx10" decimals="1" id="fact1830" unitRef="pure">77.9</mrv:ReturnOnEquity>
<mrv:EquityRatio contextRef="ctx10" decimals="1" id="fact1831" unitRef="pure">11</mrv:EquityRatio>
<mrv:OperatingMargin contextRef="ctx11" decimals="1" id="fact1837" unitRef="pure">8.1</mrv:OperatingMargin>
<mrv:GrossMargin contextRef="ctx11" decimals="1" id="fact1838" unitRef="pure">79.9</mrv:GrossMargin>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx24" decimals="1" id="fact1856" unitRef="pure">10.7</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx29" decimals="1" id="fact1861" unitRef="pure">7</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx24" id="fact1671" xml:lang="en">EBITDA-Margin</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx23" id="fact1670" xml:lang="en">EBITDA-Margin</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx22" id="fact1669" xml:lang="en">EBITDA-Margin</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx21" id="fact1668" xml:lang="en">EBITDA-Margin</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx20" id="fact1667" xml:lang="en">EBITDA-Margin</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx29" id="fact1676" xml:lang="en">Return on assets</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx28" id="fact1675" xml:lang="en">Return on assets</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx27" id="fact1674" xml:lang="en">Return on assets</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx26" id="fact1673" xml:lang="en">Return on assets</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx25" id="fact1672" xml:lang="en">Return on assets</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx34" id="fact1681" xml:lang="en">Current ratio</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx33" id="fact1680" xml:lang="en">Current ratio</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx32" id="fact1679" xml:lang="en">Current ratio</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx31" id="fact1678" xml:lang="en">Current ratio</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx30" id="fact1677" xml:lang="en">Current ratio</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx25" decimals="1" id="fact1857" unitRef="pure">12</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx30" decimals="1" id="fact1862" unitRef="pure">110.5</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:ReturnOnEquity contextRef="ctx1" decimals="1" id="fact1723" unitRef="pure">100.5</mrv:ReturnOnEquity>
<mrv:EquityRatio contextRef="ctx1" decimals="1" id="fact1724" unitRef="pure">9.8</mrv:EquityRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx26" decimals="1" id="fact1858" unitRef="pure">9.1</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx27" decimals="1" id="fact1859" unitRef="pure">12.4</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx32" decimals="1" id="fact1864" unitRef="pure">113.2</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:ReturnOnEquity contextRef="ctx9" decimals="1" id="fact1821" unitRef="pure">111.7</mrv:ReturnOnEquity>
<mrv:EquityRatio contextRef="ctx9" decimals="1" id="fact1822" unitRef="pure">8.2</mrv:EquityRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx31" decimals="1" id="fact1863" unitRef="pure">110.6</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:ReturnOnEquity contextRef="ctx6" decimals="1" id="fact1748" unitRef="pure">86.4</mrv:ReturnOnEquity>
<mrv:EquityRatio contextRef="ctx6" decimals="1" id="fact1749" unitRef="pure">9.6</mrv:EquityRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx34" decimals="1" id="fact1866" unitRef="pure">131.4</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:ReturnOnEquity contextRef="ctx11" decimals="1" id="fact1839" unitRef="pure">58.2</mrv:ReturnOnEquity>
<mrv:EquityRatio contextRef="ctx11" decimals="1" id="fact1840" unitRef="pure">13.1</mrv:EquityRatio>
<mrv:ManagementsReview contextRef="ctx1" id="fact1566" xml:lang="en">Management´s review</mrv:ManagementsReview>
<mrv:DescriptionOfPrimaryActivitiesOfEntity contextRef="ctx1" id="fact1567" xml:lang="en">Business review  Novo Nordisk Denmark A/S (secondary name Novo Nordisk Region Europe Pharmaceuticals A/S and Novo  Nordisk North West Europe Pharmaceuticals A/S) is selling medicine in the treatment areas diabetes, obesity, rare  endocrine and blood disorders as well as hormone replacement treatment. The company is located in Ãrestad in  Copenhagen, Denmark. Number of average full time employees has increased from 294 in 2024 to 299 in 2025.  Novo Nordisk Denmark A/S consist of the following four business units:  The Danish sales affiliate  The unit is a fully operational sales affiliate with focus on the distribution of the medicine produced by Novo  Nordisk A/S and Novo Nordisk Healthcare AG to patients in Denmark and Iceland. Novo Nordisk A/S and Novo  Nordisk Healthcare AG bears all the risks for launches as well as research and development, hence launch costs and  R&D costs are invoiced to Novo Nordisk A/S and Novo Nordisk Healthcare AG as service fee including a mark-up  for internal costs.  Region Europe & Canada  Service company supporting the business areas/large affiliates such as Canada, France, Germany, Italy & Malta,  Spain, UK, Business Area North & Central (Denmark, Iceland, Finland, Norway, Sweden, Switzerland), Business  Area South & West (Austria, Belgium, Luxembourg, Greece, Cyprus, Ireland, Netherlands, Portugal), Business Area  East (Czech Republic, Hungary, Poland, Romania, Serbia, Ukraine, Cluster East (Albania, Bosnia and Herzegovina,  Bulgaria, Croatia, Estonia, Kosovo, Latvia, Lithuania, Moldova, Montenegro, North Macedonia, Slovakia, Slo-  venia)). All costs, both internal and external are invoiced to Novo Nordisk A/S as service fee including a mark-up  for internal costs.  Business Area office North & Central  Service company supporting the affiliates in business area North & Central (Denmark, Iceland, Finland, Norway,  Sweden, Switzerland). All costs, both internal and external are invoiced to the affiliates in business area North &  Central and to Novo Nordisk A/S. All costs, both internal and external are invoiced to Novo Nordisk A/S as service  fee including a mark-up for internal costs.  Business Area office South & West  Service company supporting the affiliates in business area South & West (Austria, Belgium, Luxembourg, Greece,  Cyprus, Ireland, Netherlands, Portugal). All costs, both internal and external are invoiced to the affiliates in business  area South & West and to Novo Nordisk A/S. All costs, both internal and external are invoiced to Novo Nordisk A/S  as service fee including a mark-up for internal costs.  </mrv:DescriptionOfPrimaryActivitiesOfEntity>
<mrv:DescriptionOfAnyUnusualMattersAffectingRecognitionOrMeasurement contextRef="ctx1" id="fact1597" xml:lang="en">Unusual circumstances  No unusual matters have effected the financial statements for 2025.  </mrv:DescriptionOfAnyUnusualMattersAffectingRecognitionOrMeasurement>
<mrv:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs contextRef="ctx1" id="fact1599" xml:lang="en">Development in activities and financial matters  The revenue for the year totals 2.504.841 tDKK against 2.367.751 tDKK last year. Net profit from the year totals  118.803 tDKK against 86.129 tDKK last year. The revenue growth in 2025 (+170.090 tDKK) was primarily driven  by Obesity business. Outlook last year estimated a net profit in the range of 80.000-90.000 tDKK for 2025. Outcome  is higher than anticipated due to larger sales within obesity and lower costs staff cost than expected.  Management considers the result for the year satisfactory compared to last year´s result.  The full year staff cost was 337.458 tDKK against 450.591 tDKK last year. The decreasing cost base was a result of  lower capacity cost driven by management shares and bonuses. The Group reduction of workforce during 2025 had  very limited impact on this entity. Overall direct marketing investment increased to 116.497 tDKK in 2025 vs 66.212  tDKK last year resulting in an increase of other external expenses from 267.505 tDKK last year to 328.711 tDKK in  2025. The increased cost are in the areas of advertisement, conference costs and strategic projects.  Net profit as of 31 December 2025 has been influenced by a combination of continued growth in the semaglutide  portfolio related to Wegovy® and lower staff costs.  </mrv:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs>
<mrv:EntitysExposureToPriceRiskCreditRiskLiquidityRiskAndCashFlowRisk contextRef="ctx1" id="fact1612" xml:lang="en">Risks  The risks in the company are limited since Novo Nordisk A/S bears all the risks for launches and research &  development. Hence all launch costs and R&D costs are invoiced to Novo Nordisk A/S. All costs, both internal and  external, for the regional office and the business area office are (due to a service contract) invoiced to Novo Nordisk  A/S or to the affiliates in business are-as North & Central and South & West.  Development for the year relative to the expectations  In its 2024 annual report, the company forecasted that 2025 sales and costs would remain at a similar level to 2024,  with an after-tax profit or loss from ordinary activities in the range of tDKK 80,000â90,000.  The primary reason for the deviation between projected and actual revenue is continued sales growth in obesity. The  difference in net profit is mainly attributable to lower staff costs.  </mrv:EntitysExposureToPriceRiskCreditRiskLiquidityRiskAndCashFlowRisk>
<mrv:DescriptionOfExpectedDevelopment contextRef="ctx1" id="fact1622" xml:lang="en">Outlook  Sales and costs in 2026 are expected to be at a similar level as 2025, with a net profit for 2026 between 110.000-  120.000 tDKK.  The GLP-1a portfolio for both diabetes and obesity are expected to constitute an increasingly larger share of the  sales (in 2026 GLP-1 will account for 88% of the sales which equates to an increase of +1.2%p versus last year).  Direct marketing investments will be focused on Wegovy® and Ozempic® in 2026. The FTE base is not expected to  grow substantially in 2026.  </mrv:DescriptionOfExpectedDevelopment>
<mrv:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod contextRef="ctx1" id="fact1629" xml:lang="en">Events occurring after the end of the financial year  There have been no events after the financial year that affect the company's financial position.  </mrv:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod>
<mrv:StatementOfCorporateSocialResponsibility contextRef="ctx1" id="fact1632" xml:lang="en">Corporate social responsibility report and report of data ethics according to section 99a and 99d of the  Danish Financial Statements Act  Information on CSR  By reference to section 99a (7) of the Danish Financial Statements Act, corporate social responsibility report is  disclosed in the annual report for Novo Nordisk A/S. By reference to section 99d (3) of the Danish Financial  Statements Act, data ethics are also disclosed in the annual report for Novo Nordisk A/S.  https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk- annual-report-2025.pdf  https://www.novonordisk.com/investors/annual-report.html  </mrv:StatementOfCorporateSocialResponsibility>
<mrv:LinkToStatementOfCorporateSocialResponsibility contextRef="ctx1" id="fact1631" xml:lang="en">https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk- </mrv:LinkToStatementOfCorporateSocialResponsibility>
<fsa:Revenue contextRef="ctx1" decimals="-3" id="fact1700" unitRef="vEUR">2504841000</fsa:Revenue>
<fsa:OtherOperatingIncome contextRef="ctx1" decimals="-3" id="fact1702" unitRef="vEUR">595011000</fsa:OtherOperatingIncome>
<fsa:Revenue contextRef="ctx6" decimals="-3" id="fact1725" unitRef="vEUR">2367751000</fsa:Revenue>
<fsa:OtherOperatingIncome contextRef="ctx6" decimals="-3" id="fact1727" unitRef="vEUR">637622000</fsa:OtherOperatingIncome>
<fsa:RawMaterialsAndConsumablesUsed contextRef="ctx1" decimals="-3" id="fact1703" unitRef="vEUR">2273603000</fsa:RawMaterialsAndConsumablesUsed>
<fsa:OtherExternalExpenses contextRef="ctx1" decimals="-3" id="fact1704" unitRef="vEUR">328711000</fsa:OtherExternalExpenses>
<fsa:RawMaterialsAndConsumablesUsed contextRef="ctx6" decimals="-3" id="fact1728" unitRef="vEUR">2173506000</fsa:RawMaterialsAndConsumablesUsed>
<fsa:OtherExternalExpenses contextRef="ctx6" decimals="-3" id="fact1729" unitRef="vEUR">267505000</fsa:OtherExternalExpenses>
<fsa:GrossProfitLoss contextRef="ctx1" decimals="-3" id="fact1705" unitRef="vEUR">497538000</fsa:GrossProfitLoss>
<fsa:GrossProfitLoss contextRef="ctx6" decimals="-3" id="fact1730" unitRef="vEUR">564362000</fsa:GrossProfitLoss>
<fsa:EmployeeBenefitsExpense contextRef="ctx1" decimals="-3" id="fact1706" unitRef="vEUR">337458000</fsa:EmployeeBenefitsExpense>
<fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="ctx1" decimals="-3" id="fact1707" unitRef="vEUR">14292000</fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss>
<fsa:EmployeeBenefitsExpense contextRef="ctx6" decimals="-3" id="fact1731" unitRef="vEUR">450591000</fsa:EmployeeBenefitsExpense>
<fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="ctx6" decimals="-3" id="fact1732" unitRef="vEUR">12400000</fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss>
<fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx1" decimals="-3" id="fact1708" unitRef="vEUR">145788000</fsa:ProfitLossFromOrdinaryOperatingActivities>
<fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx6" decimals="-3" id="fact1733" unitRef="vEUR">101371000</fsa:ProfitLossFromOrdinaryOperatingActivities>
<fsa:OtherFinanceIncome contextRef="ctx1" decimals="-3" id="fact1710" unitRef="vEUR">12375000</fsa:OtherFinanceIncome>
<fsa:OtherFinanceExpenses contextRef="ctx1" decimals="-3" id="fact1711" unitRef="vEUR">1659000</fsa:OtherFinanceExpenses>
<fsa:OtherFinanceIncome contextRef="ctx6" decimals="-3" id="fact1735" unitRef="vEUR">17245000</fsa:OtherFinanceIncome>
<fsa:OtherFinanceExpenses contextRef="ctx6" decimals="-3" id="fact1736" unitRef="vEUR">2913000</fsa:OtherFinanceExpenses>
<fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx1" decimals="-3" id="fact1712" unitRef="vEUR">156504000</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
<fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx6" decimals="-3" id="fact1737" unitRef="vEUR">115703000</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
<fsa:TaxExpense contextRef="ctx1" decimals="-3" id="fact1713" unitRef="vEUR">37701000</fsa:TaxExpense>
<fsa:TaxExpense contextRef="ctx6" decimals="-3" id="fact1738" unitRef="vEUR">29574000</fsa:TaxExpense>
<fsa:ProfitLoss contextRef="ctx1" decimals="-3" id="fact1714" unitRef="vEUR">118803000</fsa:ProfitLoss>
<fsa:ProfitLoss contextRef="ctx6" decimals="-3" id="fact1739" unitRef="vEUR">86129000</fsa:ProfitLoss>
<fsa:LeaseholdImprovements contextRef="ctx7" decimals="-3" id="fact1750" unitRef="vEUR">173000</fsa:LeaseholdImprovements>
<fsa:LandAndBuildings contextRef="ctx7" decimals="-3" id="fact1751" unitRef="vEUR">18814000</fsa:LandAndBuildings>
<fsa:FixturesFittingsToolsAndEquipment contextRef="ctx7" decimals="-3" id="fact1752" unitRef="vEUR">17581000</fsa:FixturesFittingsToolsAndEquipment>
<fsa:PropertyPlantAndEquipment contextRef="ctx7" decimals="-3" id="fact1753" unitRef="vEUR">36568000</fsa:PropertyPlantAndEquipment>
<fsa:LeaseholdImprovements contextRef="ctx8" decimals="-3" id="fact1782" unitRef="vEUR">263000</fsa:LeaseholdImprovements>
<fsa:LandAndBuildings contextRef="ctx8" decimals="-3" id="fact1783" unitRef="vEUR">25471000</fsa:LandAndBuildings>
<fsa:FixturesFittingsToolsAndEquipment contextRef="ctx8" decimals="-3" id="fact1784" unitRef="vEUR">19648000</fsa:FixturesFittingsToolsAndEquipment>
<fsa:PropertyPlantAndEquipment contextRef="ctx8" decimals="-3" id="fact1785" unitRef="vEUR">45382000</fsa:PropertyPlantAndEquipment>
<fsa:NoncurrentAssets contextRef="ctx7" decimals="-3" id="fact1754" unitRef="vEUR">36568000</fsa:NoncurrentAssets>
<fsa:NoncurrentAssets contextRef="ctx8" decimals="-3" id="fact1786" unitRef="vEUR">45382000</fsa:NoncurrentAssets>
<fsa:ShorttermTradeReceivables contextRef="ctx7" decimals="-3" id="fact1755" unitRef="vEUR">265220000</fsa:ShorttermTradeReceivables>
<fsa:ShorttermReceivablesFromGroupEnterprises contextRef="ctx7" decimals="-3" id="fact1756" unitRef="vEUR">988713000</fsa:ShorttermReceivablesFromGroupEnterprises>
<fsa:CurrentDeferredTaxAssets contextRef="ctx7" decimals="-3" id="fact1757" unitRef="vEUR">4801000</fsa:CurrentDeferredTaxAssets>
<fsa:ShorttermTradeReceivables contextRef="ctx8" decimals="-3" id="fact1787" unitRef="vEUR">285406000</fsa:ShorttermTradeReceivables>
<fsa:ShorttermReceivablesFromGroupEnterprises contextRef="ctx8" decimals="-3" id="fact1788" unitRef="vEUR">675495000</fsa:ShorttermReceivablesFromGroupEnterprises>
<fsa:CurrentDeferredTaxAssets contextRef="ctx8" decimals="-3" id="fact1789" unitRef="vEUR">11273000</fsa:CurrentDeferredTaxAssets>
<fsa:OtherShorttermReceivables contextRef="ctx7" decimals="-3" id="fact1758" unitRef="vEUR">75513000</fsa:OtherShorttermReceivables>
<fsa:OtherShorttermReceivables contextRef="ctx8" decimals="-3" id="fact1790" unitRef="vEUR">33964000</fsa:OtherShorttermReceivables>
<fsa:DeferredIncomeAssets contextRef="ctx7" decimals="-3" id="fact1759" unitRef="vEUR">4738000</fsa:DeferredIncomeAssets>
<fsa:DeferredIncomeAssets contextRef="ctx8" decimals="-3" id="fact1791" unitRef="vEUR">4484000</fsa:DeferredIncomeAssets>
<fsa:ShorttermReceivables contextRef="ctx7" decimals="-3" id="fact1760" unitRef="vEUR">1338985000</fsa:ShorttermReceivables>
<fsa:ShorttermReceivables contextRef="ctx8" decimals="-3" id="fact1792" unitRef="vEUR">1010622000</fsa:ShorttermReceivables>
<fsa:CurrentAssets contextRef="ctx7" decimals="-3" id="fact1761" unitRef="vEUR">1338985000</fsa:CurrentAssets>
<fsa:Assets contextRef="ctx7" decimals="-3" id="fact1762" unitRef="vEUR">1375553000</fsa:Assets>
<fsa:CurrentAssets contextRef="ctx8" decimals="-3" id="fact1793" unitRef="vEUR">1010622000</fsa:CurrentAssets>
<fsa:Assets contextRef="ctx8" decimals="-3" id="fact1794" unitRef="vEUR">1056004000</fsa:Assets>
<fsa:ContributedCapital contextRef="ctx7" decimals="-3" id="fact1764" unitRef="vEUR">500000</fsa:ContributedCapital>
<fsa:RetainedEarnings contextRef="ctx7" decimals="-3" id="fact1765" unitRef="vEUR">15270000</fsa:RetainedEarnings>
<fsa:ContributedCapital contextRef="ctx8" decimals="-3" id="fact1796" unitRef="vEUR">500000</fsa:ContributedCapital>
<fsa:RetainedEarnings contextRef="ctx8" decimals="-3" id="fact1797" unitRef="vEUR">15267000</fsa:RetainedEarnings>
<fsa:ProposedDividendRecognisedInEquity contextRef="ctx8" decimals="-3" id="fact1798" unitRef="vEUR">86000000</fsa:ProposedDividendRecognisedInEquity>
<fsa:Equity contextRef="ctx8" decimals="-3" id="fact1800" unitRef="vEUR">101767000</fsa:Equity>
<fsa:ProposedDividendRecognisedInEquity contextRef="ctx7" decimals="-3" id="fact1766" unitRef="vEUR">118800000</fsa:ProposedDividendRecognisedInEquity>
<fsa:Equity contextRef="ctx7" decimals="-3" id="fact1768" unitRef="vEUR">134570000</fsa:Equity>
<fsa:OtherProvisions contextRef="ctx7" decimals="-3" id="fact1770" unitRef="vEUR">9072000</fsa:OtherProvisions>
<fsa:OtherProvisions contextRef="ctx8" decimals="-3" id="fact1802" unitRef="vEUR">12482000</fsa:OtherProvisions>
<fsa:Provisions contextRef="ctx7" decimals="-3" id="fact1771" unitRef="vEUR">9072000</fsa:Provisions>
<fsa:Provisions contextRef="ctx8" decimals="-3" id="fact1803" unitRef="vEUR">12482000</fsa:Provisions>
<fsa:LongtermLeaseCommitments contextRef="ctx7" decimals="-3" id="fact1772" unitRef="vEUR">20422000</fsa:LongtermLeaseCommitments>
<fsa:LongtermLiabilitiesOtherThanProvisions contextRef="ctx7" decimals="-3" id="fact1773" unitRef="vEUR">20422000</fsa:LongtermLiabilitiesOtherThanProvisions>
<fsa:LongtermLeaseCommitments contextRef="ctx8" decimals="-3" id="fact1804" unitRef="vEUR">28221000</fsa:LongtermLeaseCommitments>
<fsa:LongtermLiabilitiesOtherThanProvisions contextRef="ctx8" decimals="-3" id="fact1805" unitRef="vEUR">28221000</fsa:LongtermLiabilitiesOtherThanProvisions>
<fsa:ShorttermPartOfLongtermLiabilitiesOtherThanProvisions contextRef="ctx7" decimals="-3" id="fact1774" unitRef="vEUR">11916000</fsa:ShorttermPartOfLongtermLiabilitiesOtherThanProvisions>
<fsa:ShorttermTradePayables contextRef="ctx7" decimals="-3" id="fact1775" unitRef="vEUR">63271000</fsa:ShorttermTradePayables>
<fsa:ShorttermPartOfLongtermLiabilitiesOtherThanProvisions contextRef="ctx8" decimals="-3" id="fact1806" unitRef="vEUR">12202000</fsa:ShorttermPartOfLongtermLiabilitiesOtherThanProvisions>
<fsa:ShorttermTradePayables contextRef="ctx8" decimals="-3" id="fact1807" unitRef="vEUR">27531000</fsa:ShorttermTradePayables>
<fsa:ShorttermPayablesToGroupEnterprises contextRef="ctx7" decimals="-3" id="fact1776" unitRef="vEUR">977704000</fsa:ShorttermPayablesToGroupEnterprises>
<fsa:ShorttermTaxPayables contextRef="ctx7" decimals="-3" id="fact1777" unitRef="vEUR">23348000</fsa:ShorttermTaxPayables>
<fsa:ShorttermPayablesToGroupEnterprises contextRef="ctx8" decimals="-3" id="fact1808" unitRef="vEUR">697525000</fsa:ShorttermPayablesToGroupEnterprises>
<fsa:ShorttermTaxPayables contextRef="ctx8" decimals="-3" id="fact1809" unitRef="vEUR">25066000</fsa:ShorttermTaxPayables>
<fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="ctx7" decimals="-3" id="fact1778" unitRef="vEUR">135250000</fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm>
<fsa:ShorttermLiabilitiesOtherThanProvisions contextRef="ctx7" decimals="-3" id="fact1779" unitRef="vEUR">1211489000</fsa:ShorttermLiabilitiesOtherThanProvisions>
<fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="ctx8" decimals="-3" id="fact1810" unitRef="vEUR">151210000</fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm>
<fsa:ShorttermLiabilitiesOtherThanProvisions contextRef="ctx8" decimals="-3" id="fact1811" unitRef="vEUR">913534000</fsa:ShorttermLiabilitiesOtherThanProvisions>
<fsa:LiabilitiesOtherThanProvisions contextRef="ctx7" decimals="-3" id="fact1780" unitRef="vEUR">1231911000</fsa:LiabilitiesOtherThanProvisions>
<fsa:LiabilitiesAndEquity contextRef="ctx7" decimals="-3" id="fact1781" unitRef="vEUR">1375553000</fsa:LiabilitiesAndEquity>
<fsa:LiabilitiesOtherThanProvisions contextRef="ctx8" decimals="-3" id="fact1812" unitRef="vEUR">941755000</fsa:LiabilitiesOtherThanProvisions>
<fsa:LiabilitiesAndEquity contextRef="ctx8" decimals="-3" id="fact1813" unitRef="vEUR">1056004000</fsa:LiabilitiesAndEquity>
<fsa:StatementOfChangesInEquity contextRef="ctx1" id="fact1105" xml:lang="en">Statement of changes in equity  DKK thousand.  Proposed dividend  Contributed  for the financial  capital Retained earnings  year  Total  Equity 1 January 2025  500  15.267  86.000  101.767  Distributed dividend  0 0 -86.000  -86.000  Profit or loss for the year brought  forward  0 3 118.800  118.803  500  15.270  118.800  134.570  </fsa:StatementOfChangesInEquity>
<fsa:DisclosureOfAccountingPolicies contextRef="ctx1" id="fact1136" xml:lang="en">Accounting policies  The annual report for Novo Nordisk Denmark A/S has been presented in accordance with the Danish  Financial Statements Act regulations concerning reporting class C enterprises (large enterprises).  The accounting policies are unchanged from last year, and the annual report is presented in TDKK.  According to section 96 (3) of the Danish Financial Statements Act, the company has not disclosed the fee to  the auditor, as the relevant information is included in the consolidated Financial Statements of Novo Nordisk  A/S.  </fsa:DisclosureOfAccountingPolicies>
<fsa:ExplanationOfNotDisclosingCashFlowsStatements contextRef="ctx1" id="fact1143" xml:lang="en">Pursuant to section 86 (4) of the Danish Financial Statements Act, no statement of cash flows for the  enterprise has been prepared, as the relevant information is included in the consolidated financial statements  of Novo Nordisk A/S.  </fsa:ExplanationOfNotDisclosingCashFlowsStatements>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisIncludingBasesUsedForRevaluationsDepreciationAmortisationEstimatedResidualValueUsefulLifeWritedownsUpwardAndDownwardAdjustments contextRef="ctx1" id="fact1146" xml:lang="en">Recognition and measurement in general  Income is recognised in the income statement concurrently with its realisation, including the recognition of  value adjustments of financial assets and liabilities. Likewise, all costs are recognised in the income  statement, including depreciations amortisations, write-downs for impairment, provisions, and reversals due  to changes in estimated amounts previously recognised in the income statement.  Assets are recognised in the statement of financial position when it seems probable that future economic  benefits will flow to the company and the value of the asset can be reliably measured.  Liabilities are recognised in the statement of financial position when it is seems probable that future economic  benefits will flow out of the company and the value of the liability can be reliably measured.  Assets and liabilities are measured at cost at the initial recognition. Hereafter, assets and liabilities are  measured as described below for each individual accounting item.  Upon recognition and measurement, allowances are made for such predictable losses and risks which may  arise prior to the presentation of the annual report and concern matters that exist on the reporting date.  </fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisIncludingBasesUsedForRevaluationsDepreciationAmortisationEstimatedResidualValueUsefulLifeWritedownsUpwardAndDownwardAdjustments>
<fsa:DescriptionOfMethodsOfForeignCurrencies contextRef="ctx1" id="fact1159" xml:lang="en">Foreign currency translation  Transactions in foreign currency are translated by using the exchange rate prevailing at the date of the  transaction. Differences in the rate of exchange arising between the rate at the date of transaction and the rate  at the date of payment are recognised in the profit and loss account as an item under net financials.  Receivables, payables, and other foreign currency monetary items are translated using the closing rate. The  difference between the closing rate and the rate at the time of the occurrence or initial recognition in the latest  Financial Statements of the receivable or payable is recognised in the income statement under financial  income and expenses.  </fsa:DescriptionOfMethodsOfForeignCurrencies>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfIncomeStatementItems contextRef="ctx1" id="fact1167" xml:lang="en">Income statement</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfIncomeStatementItems>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue contextRef="ctx1" id="fact1168" xml:lang="en">Revenue  The enterprise is applying IFRS 15 as its basis of interpretation for the recognition of revenue.  Revenue consist of the net sales of pharmaceutical products sold to patients.  Revenue from sale of goods is recognised when Novo Nordisk Denmark A/S has transferred control of  products sold to the buyer and it is probable that Novo Nordisk Denmark A/S will collect the consideration to  which it is entitled for transferring the products.  </fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncomeAndExpenses contextRef="ctx1" id="fact1174" xml:lang="en">Other operating income  Other operating income is related to invoiced service fees to Novo Nordisk A/S and Novo Nordisk Health  care AG. Income is derived from the provision of services and is recognised as revenue at the time the  services are delivered.  </fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncomeAndExpenses>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales contextRef="ctx1" id="fact1178" xml:lang="en">Cost of sales  Cost of sales comprises costs concerning purchase of finished goods and consumables less discounts.  </fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses contextRef="ctx1" id="fact1180" xml:lang="en">Other external expenses  Other external expenses comprise expenses incurred for distribution, sales, advertising, administration,  premises, and loss on receivables.  </fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense contextRef="ctx1" id="fact1183" xml:lang="en">Staff costs  Staff costs include salaries and wages, including holiday allowances, pensions, and other social security costs,  etc., for staff members. Staff costs are less public reimbursements.  </fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense>
<fsa:DescriptionOfMethodsOfImpairmentLossesAndDepreciation contextRef="ctx1" id="fact1186" xml:lang="en">Depreciation, amortisation, and write-down for impairment  Depreciation, amortisation, and writedown for impairment comprise depreciation on, amortisation of, and  writedown relating to tangible fixed assets.  </fsa:DescriptionOfMethodsOfImpairmentLossesAndDepreciation>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses contextRef="ctx1" id="fact1189" xml:lang="en">Financial income and expenses  Financial income and expenses are recognised in the income statement with the amounts concerning the  financial year. Financial income and expenses comprise interest income and expenses, financial expenses  from financial leasing and reimbursements under the advance tax scheme, etc.  </fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="ctx1" id="fact1193" xml:lang="en">Tax on net profit or loss for the year  Tax for the year comprises the current income tax for the year and changes in deferred tax and is recognised  in the income statement with the share attributable to the net profit or loss for the year and directly in equity  with the share attributable to entries directly in equity.  The entity is jointly taxed with other group entities. The total Danish income tax charge is allocated between  profit/loss-making Danish entities in proportion to their taxable income (full absorption).  Jointly taxed entities entitled to a tax refund are reimbursed by the management company based on the rates  applicable to interest allowances, and jointly taxed entities which have paid too little tax pay a surcharge  according to the rates applicable to interest surcharges to the management company.  </fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAssetsAndLiabilities contextRef="ctx1" id="fact1202" xml:lang="en">Balance Sheet</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAssetsAndLiabilities>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment contextRef="ctx1" id="fact1203" xml:lang="en">Tangible assets  Tangible assets are measured at cost with deduction of accrued depreciation and writedown.  The depreciable amount is cost plus revaluations at fair value less expected residual value after the end of the  useful life of the asset. The amortisation period is fixed at the acquisition date and reassessed annually. If the  residual value exceeds the carrying amount of the asset, depreciation is discontinued.  If the amortisation period or the residual value is changed, the effect on amortisation will, in future, be  recognised as a change in the accounting estimates.  The cost comprises acquisition cost and costs directly associated with the acquisition until the time when the  asset is ready for use.  Depreciation is done on a straight-line basis according to an assessment of the expected useful life:  Useful life  Fixtures and furniture, other plant and equipment  </fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment>
<fsa:DisclosureOfEmployeeBenefitsExpense contextRef="ctx1" id="fact1215" xml:lang="en">10 years  Leases  The enterprise is applying IFRS 16 as its basis of interpretation for the recognition of classification and  recognition of leases.  Leases pertaining to property, plant, and equipment for which the enterprise has the right-of-use are  recognised in the statement of financial position as right-of-use assets. The assets are, at initial recognition,  measured at imputed cost, consisting of: Â ï· The imputed lease liability Â ï· Any lease payments paid prior to â or on â the starting date, less any lease incentives received Â ï· Any direct start-up costs Â ï· Any restoring costs  Hereafter, recognised leased assets are treated like the enterpriseâs remaining property, plant, and equipment.  Accounting policies  Lease liabilities are recognised in the statement of financial position as liabilities other than provision and are  measured, at initial recognition, at the present value of lease payments payable over the lease term. This  includes a purchase option in the event that the enterprise expects to purchase the right-of-use asset. When  determining the present value, the internal rate of return or, alternatively, the enterpriseâs borrowing rate is  applied as discount rate.  Hereafter, the lease liability is treated like the remaining financial liabilities, i.e. at amortised cost.  The interest element of the lease payments is recognised in the income statement over the contractual term.  The following leases are not recognised as assets and liabilities in the statement of financial position: Â ï· Leases with a duration of twelve months or less (short leases) Â ï· Leases where the replacement value of the asset is less than DKK 30,000. (low-value assets)  For such leases, the lease payment is recognised in the income statement as an expense on a linear basis over  the lease term.  Impairment loss relating to non-current assets  If there are indicators of impairment in tangible fixed assets, an impairment test will be performed.  If indications of impairment are disclosed, impairment tests are carried out for each individual asset or group  of assets, respectively. write-down for impairment is done to the recoverable amount if this value is lower  than the carrying amount.  The recoverable amount is the higher value of value in use and selling price less expected selling cost. The  value in use is calculated as the present value of the expected net cash flows from the use of the asset or the  asset group and expected net cash flows from the sale of the asset or the asset group after the end of their  useful life.  Previously recognised impairment losses are reversed when conditions for impairment no longer exist.  Receivables  Receivables are measured at amortised cost, which usually corresponds to nominal value. In order to meet  expected losses, they are written down for impairment to the net realisable value.  An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is  impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is  recognised on individual basis.  Receivables in respect of which there is no objective evidence of individual impairment are tested for  objective evidence of impairment on a portfolio basis. The portfolios are primarily based on the debtor's  domicile and credit ratings in line with the Company's risk management policy. The objective evidence  applied to portfolios is determined based on historical loss experience.  Accounting policies  Impairment losses are calculated as the difference between the carrying amount of the receivables and the  present value of the expected cash flows, including the realisable value of any collateral received. The  effective interest rate for the individual receivable or portfolio is used as discount rate.  Prepayments  Prepayments recognised under assets comprise incurred costs concerning the following financial year.  Equity  Dividend  Dividend expected to be distributed for the year is recognised as a separate item under equity.  Income tax and deferred tax  Current tax receivable and tax liabilities are recognised in the balance sheet at the amount calculated on the  basis of the expected taxable income for the year adjusted for tax on previous year's taxable income and  prepaid taxes. Tax receivable and tax liabilities are set off to the extent that legal right of set-off exists and if  the items are expected to be settled net or simultaneously.  Deferred tax is measured on the basis of temporary differences in assets and liabilities with a balance sheet  focus.  Deferred tax is measured based on the tax rules and tax rates applying under the legislation prevailing in the  respective countries on the reporting date when the deferred tax is expected to be released as current tax.  Changes in deferred tax due to changed tax rates are recognised in the income statement, except for items  included directly in the equity.  Deferred tax is measured based on the tax rules and tax rates applying under the legislation on the balance  sheet date and prevailing when the deferred tax is expected to be released as current tax.  Provisions  Provisions are measured at net realisable value or at fair value. If the fulfilment of a liability is expected to  take place far in the future, the liability is measured at fair value.  Liabilities other than provisions  Financial liabilities other than provisions related to borrowings are recognised at the received proceeds less  transaction costs incurred. In subsequent periods, the financial liabilities are recognised at amortised cost,  corresponding to the capitalised value when using the effective interest rate. The difference between the  proceeds and the nominal value is recognised in the income statement during the term of the loan.  Other liabilities are measured at amortised cost which usually corresponds to the nominal value.  2.  Staff costs  Salaries and wages  306.110  419.254  Pension costs  28.929  29.274  Other costs for social security  2.419  2.063  337.458  450.591  Average number of employees  299 294 By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to Management is  not disclosed.  Incentive programmes:  Management participates in Novo Nordisk A/S's incentive programme.  </fsa:DisclosureOfEmployeeBenefitsExpense>
<fsa:DisclosureOfRevenue contextRef="ctx1" id="fact1317" xml:lang="en">Notes  DKK thousand.  2025  2024  2025  2024  1.  Revenue  Diabetes and Obesity Care, Denmark  2.179.895  2.112.091  Diabetes and Obesity Care, Iceland  173.239  133.748  Rare Disease, Denmark  144.127  115.745  Rare Disease, Iceland  7.580  6.167  2.504.841  2.367.751  </fsa:DisclosureOfRevenue>
<fsa:AverageNumberOfEmployees contextRef="ctx1" decimals="0" id="fact1717" unitRef="pure">299</fsa:AverageNumberOfEmployees>
<fsa:AverageNumberOfEmployees contextRef="ctx6" decimals="0" id="fact1742" unitRef="pure">294</fsa:AverageNumberOfEmployees>
<fsa:DisclosureOfOtherFinanceIncome contextRef="ctx1" id="fact1339" xml:lang="en">2025  2024  3.  Financial income  Other financial income  261  297  Interest income, group enterprises  12.114  16.948  12.375  17.245  </fsa:DisclosureOfOtherFinanceIncome>
<fsa:DisclosureOfOtherFinanceExpenses contextRef="ctx1" id="fact1351" xml:lang="en">4.  Financial expenses  Interest expenses, group enterprises  343  451  Other financial expenses  1.316  2.462  1.659  2.913  Notes  DKK thousand.  </fsa:DisclosureOfOtherFinanceExpenses>
<fsa:DisclosureOfTaxExpenses contextRef="ctx1" id="fact1363" xml:lang="en">2025  2024  5.  Tax for the year  Tax charge for the year  31.124  29.738  Deferred tax adjustments in the year  6.472  -89  Adjustment of tax for previous years  105  -75  37.701  29.574  </fsa:DisclosureOfTaxExpenses>
<fsa:DisclosureOfTheManagementsProposedDistributionOfProfitLoss contextRef="ctx1" id="fact1378" xml:lang="en">Proposed distribution of net profit</fsa:DisclosureOfTheManagementsProposedDistributionOfProfitLoss>
<fsa:ProposedDividendRecognisedInEquity contextRef="ctx7" decimals="-3" id="fact1767" unitRef="vEUR">118800000</fsa:ProposedDividendRecognisedInEquity>
<fsa:TransferredToFromRetainedEarnings contextRef="ctx1" decimals="-3" id="fact1719" unitRef="vEUR">3000</fsa:TransferredToFromRetainedEarnings>
<fsa:ProposedDividendRecognisedInEquity contextRef="ctx8" decimals="-3" id="fact1799" unitRef="vEUR">86000000</fsa:ProposedDividendRecognisedInEquity>
<fsa:TransferredToFromRetainedEarnings contextRef="ctx6" decimals="-3" id="fact1744" unitRef="vEUR">129000</fsa:TransferredToFromRetainedEarnings>
<fsa:ProfitLoss contextRef="ctx1" decimals="-3" id="fact1715" unitRef="vEUR">118803000</fsa:ProfitLoss>
<fsa:ProfitLoss contextRef="ctx6" decimals="-3" id="fact1740" unitRef="vEUR">86129000</fsa:ProfitLoss>
<fsa:DisclosureOfPropertyPlantAndEquipment contextRef="ctx1" id="fact1379" xml:lang="en">DKK thousand.  7.  Property, plant and equipment  Fixtures and  fittings, other  Leasehold  Land and  plant and  improvements  property  equipment  Cost at 1 January 2025  451  35.403  34.419  Acquisitions  0 604  4.874  Retirement  0 0 -3.494  Cost at 31 December, 2025  451  36.007  35.799  Impairment losses and depreciation at 1 January  2025  188  9.932  14.771  Depreciation  90  7.261  6.941  Depreciation on assets disposed during the year  0 0 -3.494  Impairment losses and depreciation at 31  December, 2025  278  17.193  18.218  Carrying amount at 31 December, 2025  173  18.814  17.581  Lease assets are recognised at a carrying amount  of  18.814  10.539  </fsa:DisclosureOfPropertyPlantAndEquipment>
<fsa:DisclosureOfReceivables contextRef="ctx1" id="fact1432" xml:lang="en">8.  Receivables from group enterprises  Part of the balance relates to an intra-group cash pool scheme with DKK 808.722 thousand.  </fsa:DisclosureOfReceivables>
<fsa:DisclosureOfDeferredTaxAssetsAndLiabilities contextRef="ctx1" id="fact1435" xml:lang="en">31/12 2025  31/12 2024  9.  Deferred tax assets  Deferred tax assets 1 January 2025  11.273  11.184  Deferred tax of the results for the year  -6.472  89  4.801  11.273  Deferred tax assets consist of fixtures and fittings, other plant and equipment and provisions.  </fsa:DisclosureOfDeferredTaxAssetsAndLiabilities>
<fsa:ExplanationOfPrepayments contextRef="ctx1" id="fact1448" xml:lang="en">DKK thousand.  10. Prepayments  Prepayments include accrual of expenses relating to subsequent financial years, including payments for market  data, software licenses and facility expenses.  </fsa:ExplanationOfPrepayments>
<fsa:DisclosureOfContributedCapital contextRef="ctx1" id="fact1452" xml:lang="en">11. Share capital  The share capital of the Company is DKK 500.000 divided into shares of DKK 1 each. The Company was  founded 14 November 2016 and there has been no change in the share capital.  </fsa:DisclosureOfContributedCapital>
<fsa:DisclosureOfOtherProvisions contextRef="ctx1" id="fact1457" xml:lang="en">31/12 2025  31/12 2024  12. Other provisions  Other provisions 1 January 2025  12.482  44.898  Utilized  0 -32.626  Additions  6.780  31.361  Transferred to/from "Payables to Group Enterprises"  -10.190  -31.151  9.072  12.482  Other provisions comprise provisions for anniversary bonuses, totalling TDKK 750 and management and  employee shares, totalling TDKK 8.322. Management participate in a long-term share based incentive  programme linked to the performance of Novo Nordisk. These shares are anticipated to be paid out in 2027  and 2028; however, the amount is contingent upon the performance of the group.  In addition to the management programme, all employees in the Novo Nordisk group, including Novo Nordisk  Denmark A/S was offered 74 (37 before split) restricted stock units in February 2023. A stock unit gives the  right to receive one Novo Nordisk share free of charge in August 2026 subject to continued employment.  </fsa:DisclosureOfOtherProvisions>
<fsa:DisclosureOfLongtermLiabilities contextRef="ctx1" id="fact1483" xml:lang="en">31/12 2025  31/12 2024  13. Lease liabilities  Share of liabilities due between one and five years  20.422  28.221  Share of liabilities due within one year  11.916  12.202  Share of liabilities due after five years  0 0 32.338  40.423  Notes  DKK thousand.  </fsa:DisclosureOfLongtermLiabilities>
<fsa:DisclosureOfOtherPayables contextRef="ctx1" id="fact1501" xml:lang="en">31/12 2025  31/12 2024  14. Other payables  Salaries, wages and bonus  86.037  100.417  Pension contributions  4.001  4.429  Holiday pay  19.215  20.151  Accrued Expenses  25.324  25.558  Other payables  673  655  135.250  151.210  </fsa:DisclosureOfOtherPayables>
<fsa:DisclosureOfCollateralsAndAssetsPledgesAsSecurity contextRef="ctx1" id="fact1523" xml:lang="en">15.  Charges and security  The company has issued a payment guarantee to the bank, which as of 31 December 2025 amounted to  TDKK 4.623.  </fsa:DisclosureOfCollateralsAndAssetsPledgesAsSecurity>
<fsa:DisclosureOfContingentLiabilities contextRef="ctx1" id="fact1527" xml:lang="en">16.  Contractual obligations and contingencies, etc.  Novo Nordisk Denmark A/S is jointly taxed with the Danish companies in Novo Holdings A/S Group. The  joint taxation also covers withholding taxes in the form of dividend tax, royalty tax and interest tax. The  Danish companies are jointly and individually liable for the joint taxation. Any subsequent adjustments to  income taxes and withholding taxes may lead to a larger liability. The tax for the individual companies is  allocated in full on the basis of the expected taxable income.  </fsa:DisclosureOfContingentLiabilities>
<fsa:DisclosureOfRelatedParties contextRef="ctx1" id="fact1534" xml:lang="en">DKK thousand.  17.  Related parties  Controlling interest  Related Party  Novo Nordisk Region Europe A/S  Novo Alle 1  2880 Bagsværd  Denmark  Basis for control  Principle  shareholder  owns 100 %  Transactions  The Company solely discloses related party transactions that have not been carried out on an arm's length  basis, cf. section 98c(7) of the Danish Financial Statements Act.  All transactions have been carried out on an arm's length basis.  Consolidated financial statements  Information about the consolidated Financial Statements  Parent  Novo Nordisk A/S  Novo Alle 1  2880 Bagsværd  Denmark  Novo Nordisk A/S is included in the consolidated financial statements of Novo Nordisk Foundation, Tuborg  Havnevej 19, 2900 Hellerup.  Requisitioning of the  parent company's  consolidated Financial  Statements:  www.novonordisk.dk  </fsa:DisclosureOfRelatedParties>
</xbrli:xbrl>